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ABSTRACT
DNA double strand break (DSB) repair through ho-
mologous recombination (HR) is crucial to maintain
genome stability. DSB resection generates a sin-
gle strand DNA intermediate, which is crucial for
the HR process. We used a synthetic DNA struc-
ture, mimicking a resection intermediate, as a bait
to identify proteins involved in this process. Among
these, LC/MS analysis identified the RNA binding
protein, HNRNPD. We found that HNRNPD binds
chromatin, although this binding occurred indepen-
dently of DNA damage. However, upon damage, HN-
RNPD re-localized to H2Ax foci and its silencing
impaired CHK1 S345 phosphorylation and the DNA
end resection process. Indeed, HNRNPD silencing re-
duced: the ssDNA fraction upon camptothecin treat-
ment; AsiSI-induced DSB resection; and RPA32 S4/8
phosphorylation. CRISPR/Cas9-mediated HNRNPD
knockout impaired in vitro DNA resection and sen-
sitized cells to camptothecin and olaparib treatment.
We found that HNRNPD interacts with the heteroge-
neous nuclear ribonucleoprotein SAF-A previously
associated with DNA damage repair. HNRNPD deple-
tion resulted in an increased amount of RNA:DNA
hybrids upon DNA damage. Both the expression of
RNase H1 and RNA pol II inhibition recovered the
ability to phosphorylate RPA32 S4/8 in HNRNPD
knockout cells upon DNA damage, suggesting that
RNA:DNA hybrid resolution likely rescues the de-
fective DNA damage response of HNRNPD-depleted
cells.
INTRODUCTION
DNA double strand breaks (DSBs), are among the most
potent genotoxic lesions, being able to induce chromoso-
mal rearrangements (1) and therefore constituting a ma-
jor challenge to genomic stability. DSBs can occur during
physiological processes, such as DNA replication, recombi-
nation and lymphoid cell development, or can be induced
by exogenous agents such as ionizing radiation (IR) and ra-
diomimetic chemicals, including many anticancer drugs (2).
Defects in genes involved in DSB repair have been associ-
ated with a wide range of diseases, from neurodegenerative
disorders to syndromes with increased cancer risk and pre-
mature aging (3,4).
To safeguard genome stability and increase survival,
cells use two principal pathways for DSBs repair: non-
homologous end-joining (NHEJ) (5) and homologous re-
combination (HR) (6). The main difference between these
two pathways consists in the fact that NHEJ, by joining
DNA ends irrespectively of their original sequence, is error-
prone, whereas HR restores the correct information using
the sister chromatid as a faithful template.While NHEJ can
function throughout the cell cycle, HR is restricted to late S
andG2 phases (7) when sister chromatids are available (5,6).
A necessary step for HR is the generation of long 3′ single-
stranded DNA (ssDNA), obtained through the DNA end-
resection process, which is triggered by the recruitment onto
the DNA lesions of the MRN complex (MRE11–RAD50–
NBSI) and CTIP (RBBP8), which stimulates MRE11 ac-
tivity (8,9). MRE11, which is endowed of both endo and
exonuclease activity, promotes the formation of minimally
resected ends by nicking DNA in multiple positions flank-
ing the breaks, acting in concert with the recently identi-
fied EXD2 exonuclease (10). Following initial resection the
EXOI nuclease and the DNA2 helicase, in complex with
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the Bloom syndrome helicase (BLM) (11), further process
the breaks generating longer ssDNA tails, which are bound
by the RPA complex to prevent hairpin formation (12) and
to facilitate the loading of RAD51 for the strand exchange
process (13). SsDNA, generated both at the replication fork
or during the DNA resection process, is a unstable struc-
ture which is exposed to the possible hybridization with the
nascent RNA to form DNA:RNA hybrids (R-loops) (14).
Emerging evidences showed that proper processing of R-
loops during DNA repair is required to preserve genome
integrity (14). In particular, R-loop resolution driven by the
DDX1 RNA helicase was found to be essential for the HR
process in human cells and, similarly, in yeast cells in which
RNase H activity is required for the RPA recruitment dur-
ing HR (15,16).
Here, through a proteomic screening, using a synthetic
DNA mimicking a DNA-end resection intermediate, we
identified the mRNA binding protein HNRNPD (hetero-
geneous nuclear ribonucleoprotein D), as a novel player in
the resection process, which favours the DNA:RNA hybrid
removal for a proper HR resolution.
MATERIALS AND METHODS
Cell culture, DNA constructs and transfection
The HeLa cell line was obtained by the American Type
Culture Collection (ATCC, CCL-2, Manassas, VA, RRID:
CVCL 0030). Cell lines were cultured in RPMI 1640 (HeLa
cells) (Thermo Fisher Scientific, Monza MB, IT) supple-
mented with 10% fetal bovine serum (Thermo Fisher Sci-
entific), penicillin (100 U/ml), streptomycin (100 g/ml)
and 2 mM glutamine at 37◦C in 5% CO2. The plasmids
encoding the sequences of the HNRNPD isoforms (p45,
p42, p40 and p37) fused to the FLAG-tag were a gift from
R.J. Schneider,Department ofMicrobiology andRadiation
Oncology, NYU School of Medicine. The plasmid encod-
ing SAF-A-FLAG wt was a gift from Nick Gilbert, MRC
Human Genetics Unit, Institute of Genetics and Molecu-
lar Medicine, University of Edinburgh, Crewe Road, Edin-
burgh, UK. The plasmid encoding the human GFP-RNase
H1 was a gift from Robert Joseph Crouch, Developmental
Biology Division, Eunice Kennedy Shriver National Insti-
tute of Child Health and Human Development, National
Institutes of Health, Bethesda, MD, USA. To generate the
HNRNPD mutants we cloned into the pFLAG CMV-1
vector, through EcoRI and BamHI sites, the correspond-
ing DNAs amplified by PCR through the primers listed
in Supplementary Table S1. To generate the HNRNPD
mutants for E.coli expression we cloned in pET-duet vec-
tor, through the EcoRI and HindIII sites, the correspond-
ing DNAs amplified by PCR through the primers listed
in Supplementary Table S1. To generate HeLa cell lines
stably expressing ER-AsiSI (17), cells were seeded at 90%
confluence on 6-well plates and transfected with 1g of
pBABE ER-AsiSI (a gift from G. Legube, Center for Inte-
grative Biology, Universite´ Paul Sabatier, France) through
Lipofectamine 2000 Reagent (Thermo Fisher Scientific).
ER AsiSI-expressing cells were selected using puromycin
(Sigma Aldrich S.r.l, Milan IT) at the previously optimized
concentration of 5 g/ml. For silencing experiments, HeLa
cells were transfectedwith, ON-TARGETplusHumanHN-
RNPD siRNA Dharmacon, 30 nM of siCTR (D-001810–
10) or siHNRNPD (L-004079) using Dharmafect 1 accord-
ing to the manufacturer instructions. ON-TARGETplus
siRNA are optimized to achieve high reduction of off tar-
get effects. The HeLa HNRNPD knockout cells were gen-
erated through the CRISPR-Cas9 system. Briefly, cells were
transfected with the pSpCas9 (BB)-2A-Puro (PX459) V2.0
(18) (gift from Feng Zhang, Addgene plasmid #62988) con-
taining guide RNAs targeting the HNRNPD exon two
(5′-TCCTATCACAGGGCGATCAA-3′) and selected with
5g/ml of puromycin. The generated cell clones were an-
alyzed by western blot and sequencing to verify knock-
out of HNRNPD. For reconstitution experiments we gen-
erated the PAM resistant HNRNPD isoforms through the
QuikChange II Site-DirectedMutagenesis Kit (Agilent) ac-
cording to the manufacturer instructions with the primers
indicated in Supplementary Table S1.
The pCBASceI and pDRGFP plasmids were a gift from
Maria Jasin, Addgene plasmid #26477 (19) and Addgene
plasmid #26475 (20), respectively.
Antibodies and western blot
The following antibodies were used: HNRNPD
(1:1000, 07-260, Millipore, RRID:AB 2117338), HN-
RNPD (1:1000, D6O4F, Cell Signalling, Danvers, MA,
RRID:AB 2616009), RPA32 (1:5000, A300–244A, Bethyl
Laboratories, RRID:AB 185548), RPA32 S4/S8 (1:2000,
A300–245A, Bethyl Laboratories), H3 (1:1000, #9715,
Cell Signalling, RRID:AB 331563), CHK1 S345 (1:1000,
#2348, Cell Signalling), CHK1 (1:1000, #2360, Cell Sig-
nalling), GAPDH (1:1000, sc-25778, Santa Cruz, Dallas),
MRE11 (1:1000, NB100–142, Novus Biological), EXOI
(1:1000, A302–640A, Bethyl Laboratories), CtIP (1:1000,
#61142, Active Motif) SAF-A (1:1000, ab10297, Ab-
cam), RAD17 S645 (1:2000, ab3620, Abcam), FLAG-M2
(1:1000, F1804, SIGMA Aldrich), HA-tag (1:500, sc-805,
Santa Cruz Biotechnology), Lamin A/C (1:1000, #4777,
Cell Signalling), GFP (1:5000, ab6556, Abcam), His-tag
(1:1000, 05-531, Millipore). For total protein extraction,
cells were lysed at 4◦C in 50 mM HEPES pH7.5, 1%
Triton X-100, 150 mM NaCl, 5 mM EGTA, supplemented
with protease and phosphatase inhibitor cocktail (Roche
Applied Science). Lysates were clarified by centrifugation
at 10 000 × g for 20 min. Lysates containing equal amounts
of proteins, estimated through the Bradford assay (Bio-
Rad), were subjected to SDS-page. The chemiluminescent
images were obtained using the ImageQuant LAS 500 (GE
Healthcare).
Immunoprecipitation
For protein co-immunoprecipitation, HeLa cells were lysed
in protein extraction buffer as for western blot. The protein
lysate was quantified and 2 mg, for each condition, were
pre-cleared with protein G plus agarose (22851, Thermo
Fischer Scientific) 45 min at 4◦C on rocking. Immunopre-
cipitation was carried out at 4◦C on rocking over night
with either FLAG-M2 (1 g Ab to 1 mg of proteins,
F1804, Sigma Aldrich) and its negative control IgG1 (BD
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Pharmingen™), or HA-tag (5 g Ab to 2 mg of proteins,
000000011583816001, Sigma Aldrich) and its negative con-
trol IgG2 (550339, BD Pharmingen™).
RPA-ssDNA/dsDNA pull-down
Biotinylated DNA pull-down assay was performed as re-
ported by Yang and Zou (21) with some modifications
(see Figure 1). Briefly, 87 pmol of 70 nt biotinylated ss-
DNA were annealed with 87 pmol of 21 nt ssDNA, par-
tially complementary, to generate the DNA end-resection
intermediate used as bait in the proteomic screening, or
with the same amount of other, different length, ssDNAs
to generate DNA fragments either blunt or with varying ss-
DNA length. Reactions were performed in annealing buffer
(20mM NaCl, 10mM Tris–HCl pH7.5) for 3 min at 90◦C
followed by incubation 15 min at 37◦C in a water bath. An-
nealed DNA was attached to streptavidin-coated magnetic
beads (Thermo Fisher Scientific) in binding buffer (10 mM
Tris–HCl pH 7.5, 100 mM NaCl, 10% glycerol, 0.01% NP-
40) for 15 min rocking at RT followed by incubation with
or without purified RPA at RT for 30 min. At the end of
incubation, DNA-streptavidin-coated magnetic bead com-
plexes were washed twice with the binding buffer to remove
the unbound proteins and subsequently incubatedwith pro-
tein extract from HeLa enriched for the nuclear fraction at
RT for 30 min, followed by two washes before western blot
analysis or LC/MS. The DNA sequences used are listed in
Supplementary Table S1.
Cell fractionation
Cell fractionationwas performed as previously described by
Ishii et al. with minor modifications (22). Briefly, 3 × 106
cells, per condition, were collected and resuspended in 200
l of CSK buffer (10 mM PIPES pH 6.8, 100 mM NaCl,
300 mMMgCl2, 1 mMEGTA, 1 mMDTT, 0.1% Triton X-
100, 0.34M sucrose) supplemented with protease and phos-
phatase inhibitors and kept 5 min on ice. The soluble cy-
toplasmic fraction (S) was separated from nuclei (P) by 4
min centrifugation at 1300 × g at 4◦C. The P fraction was
washed with CSK then resuspended in 200 l of ‘western
blot buffer’, sonicated and centrifuged for 30 min at 4◦C at
10 000 × g. Following SDS-PAGE, samples were analyzed
by western blot with the indicated antibodies. For DNase I
treatment the P fraction was incubated with 80U of DNase
I (Roche Applied Science, Mannheim Germany) for 30 min
at 30◦C followed by 30min centrifugation at 1300 × g at
4◦C to obtain the solubilized fraction (S1) and pellet post
DNase A (P1).
Immunofluorescence and UVC micro-irradiation
HeLa cells, grown on glass coverslips, were fixed with
4% paraformaldehyde and permeabilized with 0.5% triton.
Samples were blocked 10 min in 1%BSA at RT and incu-
bated 1 h with anti-BrdU (1:200, 347580, BD Biosciences)
or anti-H2Ax S139 (1:600, 05-636, Millipore) 37◦C. Af-
ter washing, samples were incubated 45 min at 37◦C with
AlexaFluor 594-conjugated chicken anti-rabbit and 488-
conjugated rabbit anti-mouse or 555-conjugated goat anti-
mouse IgG (H+L) (Life Technologies), and analyzed with
a Zeiss LSM100 confocal microscope.
UVC micro-irradiation was performed as described by
Suzuki et al. (23), then the following antibodies were used
for protein detection HNRNPD (1:200, 07-260, Millipore),
H2Ax S139 (1:600, 05-636, Millipore).
Flow cytometry analysis
Upon 48 h post transfection with siRNA, HeLa cells were
treated or not with 1 M camptothecin (CPT) (Sigma
Aldrich) for 2 h and processed as reported by Forment et al.
(24) with some modifications. Briefly, 1 × 106 HeLa cells,
per condition, were resuspended in CSK buffer + 0.5% Tri-
ton + 0.3 mg/ml RNase A solution with protease inhibitors
and incubated for 5 min on ice. At the end of incubation
cells were washed twice with CSK buffer followed by cen-
trifugation for 3 min a 1300 × g at 4◦C. Afterwards, cells
were fixed with 4% paraformaldehyde for 15 min at RT,
washed twice in PBS1X and re-suspended in 100 l of in-
cubation buffer (PBS 1× + 0.5% Saponin) for 1 h with,
RPA (1:200, A300-244A, Bethyl Laboratories) or H2Ax
S139 (1:200, 05-636, Millipore) at 37◦C. After two washes
with incubation buffer, samples were incubated 45 min at
37◦C with Alexa Fluor 594-conjugated chicken anti-rabbit
or 488-conjugated rabbit anti-mouse (ThermoFisher Scien-
tific). The percentage of positive cells was determined using
the CellQuest Software (Becton Dickinson).
The ssDNA formation assay was performed as reported
previously (25) with somemodifications. Briefly, HeLa cells,
24 h after transfection with the indicated siRNAs, were
pulse-labelled for additional 24 h with 10 M BrdU and
treated with 1 M CPT for 2 h. In order to quantify the
amount of resected ssDNA we worked in non-denaturing
conditions. Cells were harvested by trypsinization. After
washing with the PBS1X, 1 × 106 cells for each experimen-
tal point were fixed in PBS 1× + 4% paraformaldehyde for
15 min at RT followed by permeabilization with PBS 1×
containing 0.1% Triton X-100 for 30 min at RT. Cells were
washed in PBS 1× twice and re-suspended in 100l of in-
cubation buffer (PBS 1× + 0.5% Saponin) with the anti-
BrdU antibody (1:100, clone B44, 347580, BD Biosciences)
for 1 h at RT or just incubation buffer as control. Cells were
washed with incubation buffer and resuspended with 100l
of 488-conjugated rabbit anti-mouse (Thermo Fisher Sci-
entific) for 45 min at RT. The percentage of BrdU positive
cells was determined using the CellQuest Software (Becton
Dickinson). The threshold level identifying FITC positivity
was set following comparison with cells incubated with only
the secondary antibody.
Nuclear extract preparation
Nuclear extracts were prepared as previously reported (26).
The nuclear fraction was dialyzed over night at 4◦C in 10
mM Tris–HCl pH 7.5, 100 mM NaCl, 10% glycerol, 0.01%
NP-40.
SMART
SMART (single molecule analysis of resection tracks) was
carried out as previously described by Cruz-Garcia et al.
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(27). The same number of control and HNRNPD silenced
cells was spotted onto the slides, so, presumably, the same
DNA content attached to the slides, although we have not
assessed this. However the SMART technique was used to
gain a snapshot visual assessment of the effect ofHNRNPD
silencing on bulk ssDNA amount upon CPT.
ER-AsiSI resection assay
GenomicDNA extraction and preparation for themeasure-
ment of resection in mammalian cells was performed as
previously (28) described with some modifications. Briefly,
HeLa cells, stably expressing the ER-AsiSI system (gift
from Gaelle Legube CBI-Centre de Biologie Integrative-
Toulouse), were treated with or without 300 nM of 4-OHT
(Sigma Aldrich) for 4 h. Cells were then trypsinized and
resuspended in 0.6% Low gelling agarose (Sigma Aldrich)
at a concentration of 6 × 106 cells/ml. Fifty microliters
of cells were spotted onto a piece of Parafilm to produce
an agar solid ball, which was then resuspended in 1 ml
of ESP buffer (0.5 M EDTA, 2% N-lauroylsarcosine, 1
mg/ml proteinase-K, 1 mM CaCl2, pH 8.0) for 20 h at
16◦C with rotation followed by treatment with 1 ml of HS
buffer (1.85 M NaCl, 0.15 M KCl, 5 mM MgCl2, 2 mM
EDTA, 4 mM Tris, 0.5% Triton X-100, pH 7.5) for 20 h
at 16◦C with rotation. After 6X washes of 10 min each
with ice cold PBS1X (8 mM Na2HPO4, 1.5 mM KH2PO4,
133 mM KCl, 0.8 mM MgCl2, pH 7.4) at 4◦C, the agar
ball was melted at 70◦C for 15 min and then diluted 15-
fold with 70◦C of ddH2O. The DNA was diluted with an
equal volume of 2X NEB 3.1 buffer. Twenty microliters of
genomicDNAwere digested ormock digested with 20 units
of BamHI-HF (NEB) over night at 37◦C. Four microliters
were used as template for the real time quantitative PCR
reaction (qRT-PCR) with the indicated primers using the
SYBR Green real time master mix (Thermo Fisher Scien-
tific). All qRT-PCR reactions were performed in a 7900HT
fast-RealTimePCR (Applied Biosystem). The Ct value
was calculated by subtracting the Ct value of the mock-
digested sample from the Ct value of the digested sample.
The %ssDNA = 1/(2(Ct-1)+0.5) × 100 (28). The sequences
of primers used are listed in Supplementary Table S1.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out as reported by Lee et al. (29) with
some modifications. HeLa cells expressing ER-AsiSI were
mock-treated or treated with 300 nM of 4-OHT for 1 h.
Cells were cross-linked with 1% formaldehyde for 10 min at
37◦C followed by inactivation with 0.125 M glycine. Cells
were washed twice with ice cold PBS 1X; for each condi-
tion 1× 106 cells were re-suspended in ChIP lysis buffer (50
mM Tris–HCl pH 8, 10 mM EDTA pH 8, SDS 0.1% and
protease inhibitors) and incubated 10 min on ice followed
by sonication (20 s-on/10 s-off twelve times at 90%of ampli-
tude using Sonics Vibra-Cell Sonics, Newtown, CT, USA).
Lysate was clarified for 30 min at 14 000 rpm at 4◦C and
diluted tenfold with the dilution buffer (50 mM Tris–HCl
pH 8, 150 mMNaCl, 1% Triton X-100, SDS 0.1% and pro-
tease inhibitors). FLAGM2 antibody (Sigma Aldrich) was
used to immunoprecipitate the HNRNPD p45-FLAG or
SAF-A-FLAGwt over night at 4◦C. To isolate the immuno-
complexes, 20 l of protein G plus agarose (Thermo Fisher
Scientific) was added to each sample and incubated, on
rocking, 45min at 4◦C.The pellets were sequentially washed
with low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM
EDTA pH8, 20 mM Tris–HCl pH8, 50 mM NaCl), high
salt buffer (0.1% SDS, 1%TritonX-100, 2mMEDTApH8,
20 mM Tris–HCl pH 8, 500 mM NaCl), LiCl buffer (0.25
M LiCl, 1% NP40, 1 mM EDTA pH 8, 1% deoxycholate
acid, 10 mM Tris–HCl pH 8) and TE buffer twice (10 mM
Tris–HCl ph8 and 1mM EDTA) followed by cross-link re-
version in elution buffer (1%SDS and 0.1MNaHCO3)with
270 mMNaCl at 65◦C for 4 h. Protein digestion was carried
out by adding 12 mM EDTA pH 8, 54 mM Tris–HCl pH 8
and 30 g of proteinase K for 1 h at 45◦C. DNA was recov-
ered by phenol/chloroform extraction and analyzed, with
the indicated primers, using a SYBR Green real time mas-
ter mix (Thermo Fisher Scientific). All qRT-PCR reactions
were performed in a 7900HT fast-RealTimePCR (Applied
Biosystems). Primers sequences used as qRT-PCR are listed
in Supplementary Table S1 (28). Data are reported as mean
± s.d. of three independent experiments. IP efficiency was
calculated as % of immunoprecipitated input DNA.
Cell cycle profile
For DNA content analysis cells were fixed in ice-cold
70% ethanol at –20◦C. At least 10 000 cells were ana-
lyzed by FACS (Becton Dickinson) following staining with
5 mg/ml propidium iodide and 0.25 mg/ml RNase A treat-
ment (Sigma-Aldrich).Datawere analyzed through theCel-
lQuest Software (Becton Dickinson).
Quantitative real time PCR
Total RNA was extracted using Trizol (Life Technolo-
gies) and treated with TurboDNase (Life Technologies).
1 g of RNA was retro-transcribed using the Superscript
VILO cDNA synthesis kit (Life Technologies). cDNA
samples were amplified by real-time quantitative reverse
transcriptase-PCR (qRT-PCR) using SYBR Green PCR
Master Mix (Life Technologies) with the primers listed in
SupplementaryTable S1. Expression levels were normalized
to those of the -actin gene.HNRNPD,MRE11, CTIP and
EXOI expression levels in siHNRNPD cells were calculated
by the 2–Ct method relatively to siCTR control cells.
Colony formation assay
For clonogenic assays, 300 cells were seeded in 24-wells
plates and either untreated or treated with the indicated
doses of CPT or olaparib (Selleckem) and incubated for 10
days. Colonies were counted after fixation with methanol
and staining with crystal violet.
In vitro DNA end-resection assay
Nuclear proteins from HeLa wt and HNRNPD KO cl10
were purified as described above for nuclear extract prepa-
ration, followed by dialysis over night at 4◦C in 50 mM
Tris–HCl pH 7.5, 50 mMNaCl, 2 mMMgCl2, 1 mMDTT
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and 0.1 mg/ml BSA. A DNA plasmid vector was digested
with KpnI (5′ overhangs), HindIII (3′ overhangs) or EcoRV
(blunt ends) followed by column purification (Qiagen, Ger-
mantown, MD, USA). The reactions were carried out in a
final volume of 20 l with 5 g of nuclear proteins, per con-
dition, and 300 ng of linearized DNA vector for the indi-
cated time points followed by incubation in 10 mM EDTA,
0.25% SDS and 100g/ml proteinase K for 10 min at 37◦C.
DNAproducts separated on 0.8% agarose were stainedwith
ethidium bromide.
DNA–RNA immunoprecipitation (DRIP)
DNA–RNA immunoprecipitation was carried out as re-
ported by Li et al. (15) with some modifications. HeLa ER-
AsiSI were transfected with siCTR or siHNRNPD for 48
h followed by treatment with 4-OHT 300 nM for 4 h. For
each condition, 5× 106 cells were re-suspended in TE buffer
(10 mM Tris–HCl pH 7.5 + 0.5 mM EDTA) + 0.5% SDS
+ 300 g/ml proteinase K a 37◦C over night under agi-
tation. At the end of incubation, the DNA:RNA hybrids
were extracted with the phenol/chlorophorm protocol; the
precipitate was washed with 70% of EtOH and air dried.
The pellet was resuspendend in 100 l of H2O and di-
gested over night with 50 U of each of the following restric-
tion enzymes (BsaI, BstXI, NdeI, EcoRI, EcoRV) in 1X re-
striction buffer. DNA:RNA hybrids were purified through
phenol/chlorophorm. The pellet was resuspended in 50 l
of water and treated or mock treated with 15 U di RNase H
(18021071, Thermo Fischer Scientific) in a final volume of
100 l and incubated over night at 37◦C. DNA:RNA hy-
brids were purified through phenol/chlorophorm and re-
suspended in 50 l of H2O. 5g of digested DNA were in-
cubated with 10 g of S9.6 antibody (ENH001, Kerafast)
in binding buffer (10 mM Tris–HCl ph 7.5, 1 mM EDTA,
10 mM NaPO4, 140 mM NaCl, 0.05% Triton X-100) over
night a 4◦C. At the end of incubation, we added 20 l
of protein G plus agarose (22851, Thermo Fischer Scien-
tific) for 2 h at 4◦C on rocking; washed three times with
binding buffer and elution of immunocomplexes with five
times of protein G volume with 50 mM Tris–HCl pH 7.5,
10 mM EDTA, 0.5% SDS, 500 g/ml proteinase K for 45
min at 55◦C. DNA:RNA hybrids were purified with the
phenol/chlorophorm protocol and resuspended in 50 l of
H2O. Four microliters were used as template for the real
time quantitative PCR reaction (qRT-PCR) with primers
amplifying a region which is ∼600 bp from the AsiSI-
induced DSB site (listed in Supplementary Table S1 DSB-
F/R ChIP and DRIP) using the SYBR Green real time
master mix (Thermo Fisher Scientific).
RPA complex cloning and purification
Molecular cloning of the wt RPA complex was performed
in pET-duet vector with the primers listed in the Supple-
mentary Table S1. Purification of wt RPAwas performed as
reported previously (30). Briefly, wt RPA was transformed
in BL21 DE3 (Rosetta) followed by induction with 300 M
IPTG for 4 h. The bacterial pellet was resuspended in lysis
buffer (50 mMNaH2PO4 pH 7, 300 mMNaCl, 15 mM Im-
idazole and 10% glycerol followed by sonication). The Ni-
NTA resin was used for affinity purification for 2 h at 4◦C.
At the end of incubation time, the resinwaswashed six times
with 10 mMTris–HCl pH 8, 300 mMNaCl and scalar con-
centration of imidazole from 10 mM to 60 mM. The RPA
complex was eluted with 10 mM Tris–HCl pH 8, 300 mM
NaCl and 300 mM imidazole. The dialysis was carried out
over night at 4◦C with 100 mMNaCl, 10 mMTris–HCl pH
7.5, 10% glycerol and 0.01% NP40.
Homologous recombination reporter assay
HeLa cells stable expressing the reporter plasmid pDR-
GFP, were transfected with the pDR-GFP plasmid (20)
(gift from Maria Jasin, Addgene plasmid #26475) and se-
lected with puromycin. HeLa pDRGFP cell lines were co-
transfected with the coding plasmid for the endonuclease I-
SceI (pCBA SceI, a gift fromMaria Jasin, Addgene plasmid
#26477(19) and the siCTR, siHNRNPD or siMRE11 (L-
009271, Dharmacon). Upon 48 h of incubationwe analyzed
the GFP values (as a readout of HR frequency) through the
FACS analysis.
Identification by LC–MS/MS
Peptide sequencing was performed on a Nano-scale by LC–
ESI/MS–MS (31). LC–MS system consists of PHOENIX
40 (ThermoQuest Ltd., Hemel Hempstead, UK) connected
to LCQDECA Ion-Trapmass spectrometer (Finnigan, San
Jose, CA, USA). Twenty microliters of trypsin-digested so-
lutions were injected in a six-port valve and were trapped
in a C18 trapping column (20 mm × 100 m ID × 360
m OD, Nano-separations, Nieuwkoop, NL) using 100%
HPLC grade water + 0.1% v/v formic acid (solvent A) at
a flow rate of 5 l/min for 10 min. A pre-column split-
ter restrictor enabled the flow rate to be set at 100–125
nl/min on a C18 analytical column (30 cm × 50 m ID
× 360 m OD, Nano-separations). Analytical separation
was performed using a linear gradient up to 60% acetoni-
trile + 0.1% (v/v) formic acid (solvent B) for 60 min. At
the end of separation, trapping and analytical columns were
washed for 10 min in 100% solvent B and were equilibrated
for 10 min in 100% solvent A. An ESI needle, composed
of gold-coated fused silica (5 cm × 25 m ID × 360 m
OD, Nano-separations), was heated to 195◦C and 2 kV was
applied for stable spray operation. Xcalibur™ 1.2 software
(Thermo) managed the LC pump and the automatic spec-
tral recording. MS/MS ion search was performed in Swiss-
Prot/UniprotKB databases using MASCOT. We set Homo
sapiens as taxonomy, peptide precursor charge at 2+ or 3+,
mass tolerance at ±1.2 Da for precursor peptide and ±0.6
Da for fragment peptides, only one missed cleavage site as
acceptable, carbamidomethylation of cysteine as fixedmod-
ification, and methionine oxidation as possible modifica-
tion. Peptides with individual ion scores –10*log[P] were
considered significant. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consor-
tium via the PRIDE (32) partner repository with the dataset
identifier PXD012045 and 10.6019/PXD012045.
Statistical analysis and reproducibility
Paired two-sided Student’s t test was used to compare the
means of twomatched groups;P< 0.05 was considered sta-
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tistically significant. Representative experiments are shown
out of at least two independent ones; detailed information
(number of independent experiments, P-values) are listed in
the individual figure legends.
RESULTS
Proteomic screen for the identification of new proteins in-
volved in DNA end-resection
Recently, the ubiquitin ligase complex, PRP19, was identi-
fied as a novel player in the DNA damage response (DDR)
by using biotinylated ssDNA in complex with RPA as a bait
to identify binding proteins that could favour ATR activa-
tion (33). Here, we created a modified DNA structure in
order to discover new proteins involved in the DNA end-
resection process. To this aim, we annealed two different
length DNA oligos, one of which was biotin-conjugated,
forming a 21 bp dsDNA with a 49 nt protruding end,
complexed with the in vitro purified wild type RPA het-
erotrimeric complex (34,35) (Figure 1A). Such structure,
which mimics a DNA end-resection intermediate, was chal-
lenged with a nuclear-enriched protein extract from HeLa
cells followed by a streptavidin pull-down assay. Bound pro-
teins were identified upon tryptic digestion through mass
spectrometry. From the analysis of the peptides associ-
ated with the RPA–DNA complex, beyond the RPA com-
plex, three proteins were identified having significant Mas-
cot scores in the Swiss-Prot/Uniprot KB database (Sup-
plementary Figure 1a): X-ray repair cross-complementing
protein 6 (XRCC6), also known as KU70, a key player of
NHEJ, which rapidly binds DSBs (36); heterogeneous nu-
clear ribonucleoprotein A 1 (hnRNPA1), involved in var-
ious aspects of RNA metabolism and known to interact
with telomeric DNA to regulate telomere length (37,38);
and HNRNPD, also known as AUF1, a key factor in the
regulation of mRNAs involved in proliferation, senescence
and stress response, which consists of four different iso-
forms (p37, p40, p42, p45) deriving from alternative splicing
(39).
HNRNPD binds the chromatin DNA
HNRNPDwas recently described to regulate, at themRNA
level, genes involved in theDDR thereby preserving genome
stability through its activity on mRNAs (40). So, we set out
to study the direct involvement of HNRNPD in the DDR.
First, we verified HNRNPD ability to bind the synthetic
DNA structure used as bait. Upon DNA pull-down and
western blot, we found that HNRNPD is indeed able to
bind to the synthetic DNA structure regardless whether the
DNAwas pre-coatedwith theRPAcomplex (Figure 1B). To
test HNRNPD ability to bind the synthetic DNA sequence
or its extremities, we used a reverse complementary syn-
thetic DNA with either free or biotin-blocked ds-ends and
found that HNRNPD binding was impaired by DNA-end
blocking suggesting a possible role in the recognition of the
DSB itself (Figure 1C). To test whether HNRNPD effec-
tively binds cellular DNA, we performed chromatin purifi-
cation, in the presence of RNase A, fromHeLa cells treated
with the topoisomerase I inhibitor camptothecin (CPT) (41)
followed by western blot. CPT is a S-phase specific drug
that inhibits the re-joining step of cleavage/religation upon
topoisomerase I action (42), inducing the collapse of the
replication fork and subsequent HR activation (43). We
found thatHNRNPD is able to bind chromatin. Indeed, the
treatment of the chromatin-containing pellet fraction (P1)
with DNase I actively releases HNRNPD (S1), although
the binding is independent from the DNA damage stimu-
lus (Figure 1D).
HNRNPD is an RNA binding protein with two RRM
motifs conferring the binding activity to the mRNAs (44)
and to the human single strand telomeric repeats (45). To
assess whether the DNA binding ability of HNRNPD re-
lies on the RRM motifs or other domains, we generated
HNRNPD deletion mutants (Figure 1E) and tested their
ability to bind chromatin upon enriched purification from
HeLa cells treated or not with CPT; all the purification
steps were carried out following treatment with RNase A.
We found that only the mutant protein (E) containing the
whole 100aa C-terminal portion was able to bind the chro-
matinDNA;whereas themutants containing either one (C),
or both RRM motifs (D), without the C-terminal region,
were not (Figure 1F and data not shown for mutants A
and B). To confirm that the loss of binding ability of mu-
tants C and D was indeed due to their intrinsic nature and
not to their lower expression, which could be below the
technique detection threshold, we performed western blot
analysis of the soluble and insoluble fraction using higher
amounts of protein extracts, confirming the DNA binding
defects of both mutants (Supplementary Figure 1b). Then,
we tested the ability of HNRNPD mutants, transfected in
HeLa cells, to bind the synthetic biotinylated DNA struc-
ture through streptavidin pull-down. Protein lysates were
treated with RNase A to remove possible interferences by
RNA molecules. As reported in supplementary Figure 1c,
both endogenous and overexpressedHNRNPDwt proteins
were able to bind the synthetic DNA. Consistent with the
chromatin binding ability, the RRM2+C-terminal (E) dele-
tion mutant preserves the DNA binding ability, contrary
to the RRM1+RRM2 (D) mutant (Supplementary Figure
1c). Finally, we purified human recombinant His-tagged
RRM1+RRM2 (D) or RRM2+C-terminal (E)mutant pro-
teins expressed in E. coli to reduce the chance of pulling
down interacting proteins; a streptavidin pull-down assay
with the biotinylated DNA structure, confirmed that the
E RRM2+C-terminal mutant retained its binding capacity
whereas the D mutant did not (Supplementary Figure 1d).
We could not test the C-terminal only because of difficulties
in achieving its expression. Collectively, these data showed
that HNRNPD is able to bind both DNA synthetic struc-
tures as well as chromatin from HeLa cells, independently
of RNA; the DNA binding activity of HNRNPD likely re-
quires the free DNA ends and the C-terminal protein do-
main, which, interestingly, contains a glycine–arginine rich
domain (GAR) (46), which may favour its localization to
the DSBs, as discussed below. Protein loading onto chro-
matin does not change in presence ofDNAdamage suggest-
ing a possible protein re-localization upon DNA breaks.
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Figure 1. Proteomic screen and HNRNPD chromatin binding ability. (A) Schematic representation of the proteomic screen by using a synthetic DNA
structure coated with the heterotrimeric RPAwt complex, including the 70, 32 and 14 kDa isoforms, which was used as bait for the proteomic screen
after being challenged with HeLa nuclear extracts. (B) DNA pull down assay of the synthetic DNA structure coated or not with the recombinant RPA
complex produced in E. coli (input) followed by western blot analysis with the indicated antibodies. HeLa nuclear extract was incubated for 30 min with
0,3 mg/ml of RNase A on ice, followed by centrifugation to remove debris. (Sequences are listed in Supplementary Table S1). (C) DNA pull-down of
the schematically indicated biotinylated DNA structures (Sequences are listed in Supplementary Table S1). Biotin is represented as black dots. Western
blot analysis was performed with the indicated antibodies. The asterisk indicates a non-specific band (which appears using the Millipore antibody). (D)
Chromatin enriched purification was performed upon 2 h treatment with 1M of CPT followed by western blot analysis. DNase I treatment of the first
pellet fraction (P) was performed, when indicated, with 80U of enzyme for 30 min at 30◦C originating a new supernatant and pellet fraction (S1 and P1
respectively). All the purification steps were performed upon incubation for 30min with 0,3 mg/ml of RNase A on ice, followed by centrifugation to remove
debris. H3 and GAPDH were used as markers for the chromatin and soluble fractions, respectively. RAD17 S645 was used as a DNA damage control.
(E) Schematic representation of HNRNPD deletion mutants. (F) HeLa cells were transfected with the indicated DNA, followed by 48 h of incubation.
Chromatin enriched purification was performed upon 2 h treatment with 1M of CPT followed by western blot analysis. All the purification steps were
performed upon incubation for 30 min with 0.3 mg/ml of RNase A on ice, followed by centrifugation to remove debris. H3 and GAPDH were used as
markers for the chromatin and soluble fractions, respectively. RPA32 was used as a DNA damage control.
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HNRNPD localizes at the sites of DNA damage and its si-
lencing impairs the DDR
The ability of DNA repair factors to re-localize to DNA
damage sites is a prerogative for the correct DDR. So, to
test whether HNRNPD can move from undamaged DNA
to specific damage sites, we used micro irradiation coupled
with BrdU treatment, to induce localized DSBs (23). In-
terestingly, 30 min after 25 J/m2 of UVC laser irradiation,
we observed an increased number of HNRNPD foci most
of which showed colocalization with H2Ax (Ser139) foci
(Figure 2A). The DDR is regulated by multiple phospho-
rylation events, which include signals for the repair factors
ultimately involved in the processing of the DNA lesions.
The down-regulation of any of these proteins can affect
genome stability (47). Here, to gain insight into the function
of HNRNPD within the DDR, we silenced HNRNPD ex-
pression in HeLa cells using specific siRNAs and analyzed
the expression of key DDR players in response to CPT. We
found that, upon CPT treatment and with respect to con-
trol cells (siCTR), HNRNPD silenced cells (siHNRNPD)
had reduced levels of CHK1 S345 phosphorylation, a cru-
cial event for the activation of the DNA damage check-
point, suggesting that HNRNPD silencing impairs check-
point activation (Figure 2B). Moreover, the phosphoryla-
tion of RPA32 S4/8, a marker of replication checkpoint ac-
tivation and, importantly, ofDNAend-resection (11,48,49),
was reduced in HNRNPD silenced cells, as shown by west-
ern blot analysis (Figure 2B). Importantly, HNRNPD si-
lenced cells showed a similar cell cycle profile compared
with control cells, indicating that the down-regulation of
RPA32 phosphorylation, in siHNRNPD cells, could not be
reasonably explained by cell cycle-dependent differences as
opposed to HNRNPD knockdown (Figure 2C). The CPT
treatment induces activation of H2Ax andMRN complex
for the proper repair of the DNA DSBs (50). We analyzed
the impact of HNRNPD silencing on the DNA repair ki-
netics, measured as H2Ax foci resolution upon the DNA
damage induction. First, we showed a normal H2Ax acti-
vation in response to DNA damage, upon 30 min of CPT in
siHNRNPD cells compared to siCTR, consistent with cor-
rect lesion recognition (51) (Figure 2D). Moreover, upon
6 h from CPT washout, HeLa siCTR cells reduced the
H2Ax foci up to 50%. Conversely, HeLa HNRNPD si-
lenced cells showed an impaired foci resolution, as for the
siMRE11 cells, consistent with inability to repair the DSBs
(Figure 2E). We have not assessed here the effect of HN-
RNPD silencing on H2Ax foci formation in basal condi-
tions (no DNA damage induction) although a possible role
in telomere dysfunction-induced foci has been previously
found (52).
Overall, these data further support a possible involve-
ment of HNRNPD in the DNA damage response and in
the processing of the DNA lesions.
HNRNPD is involved in the DNA end-resection process
The HR repair pathway requires DNA end-resection in or-
der to produce ssDNA tails needed for the invasion of the
complementary strand used as template for an error-free re-
pair (53). To assess HNRNPD role in this process, we first
analyzed, by cytofluorimetric analysis, the BrdU accumula-
tion under non-denaturing condition as a surrogate marker
of ssDNA formation upon CPT (9). We found a reduc-
tion of ssDNA formation inHNRNPD silencedHeLa cells,
compared with control cells, following 48 h of silencing and
24 h of BrdU labelling, upon 1 h of drug treatment (Fig-
ure 3A and Supplementary Figure 2a). HNRNPD protein
depletion seemed to impair ssDNA formation only in the
DNAdamage condition and not following replication stress
(Supplementary Figure 2b).We used the SMART technique
(27) to gain a snapshot visual assessment of the effect of
HNRNPD silencing on ssDNA upon CPT. Indeed, HN-
RNPD silencing markedly reduced BrdU bulk immunoflu-
orescence upon CPT treatment compared with the siCTR
cells (Figure 3B and C). So, we asked whether HNRNPD
down regulation affects the DNA end resection process (54)
and decided to assess more precisely the extent of ssDNA
formation; to this aim, we generated HeLa cells expressing
the inducible ER-AsiSI system to create DSBs in vivo at
specific loci (28). Cell treatment with 4-hydroxytamoxifen
(4-OHT) induces the nuclear localization of the engineered
AsiSI endonuclease followed by DSBs, repaired through
the DNA end-resection and HR (28). The percentage of
resected DSBs was calculated by qPCR using two sets of
primers, amplifying two regions that include BamHI sites
located at 364 and 1754 bp from the AsiSI break site and
therefore able to identify a quite wide range of resection.
Surprisingly, HNRNPD knockdown markedly reduced the
efficiency of DNA end-resection at both sites, positioning
HNRNPD upstream to this process (Figure 3D and Sup-
plementary Figure 2c). As a control, given that HNRNPD
is one of the principal RNA binding protein involved in
mRNA fate (40), we checked whether its silencing could af-
fect the mRNA and protein levels of key players underlying
the DNA end resection process. We found that HeLa siHN-
RNPD cells showed unperturbed levels of MRE11, EXO1,
CTIP, (Supplementary Figures 2d–f).
The extended ssDNA tails, produced through DNA end-
resection, are rapidly coated by the heterotrimeric RPA
complex. Consistent with the affected DNA end-resection
process, HeLaHNRNPD silenced cells showed an impaired
RPA32 DNA binding compared with the control cells in
response to CPT, measured by FACS analysis (Figure 3E)
(24). Indeed, HNRNPD silencing in HeLa ER-AsiSI re-
duced RPA32 DNA binding ability upon DNA damage
induction measured through ChIP analysis (Supplemen-
tary Figure 2g). Similarly, upon transfection of the FLAG
tagged HNRNPD p45 protein isoform and DSB induc-
tion, we demonstrated HNRNPD increased presence near
the region proximal to the AsiSI cut sites through ChIP
analysis (Figure 3F and Supplementary Figure 2h). Finally,
we generated HeLa cell lines stably expressing the pDR-
GFP system in order to verify the impact of HNRNPD
down-regulation on HR efficiency (19,20). The transfec-
tion of the I-SceI endonuclease in pDR-GFP cells induces
DSBs, which activate the endogenous HR repair pathway
that in turn leads to functional GFP reconstitution; the co-
transfection with siRNAs against HNRNPD reduced the
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Figure 2. HNRNPD regulates the DNA damage response. (A) HeLa cells were incubated with 10 MBrdU for 16 h followed by exposure to 50 J/m2 of
UVC to induce localizedDSBs, and cells were allowed to incubate for 1 h before fixation. Immunofluorescence was performedwith the indicated antibodies.
Lower panel: ImageJ analysis of laser irradiation images to quantify the number of HNRNPD foci × cell before and after irradiation. Data represent the
mean ± standard deviation (s.d.). (n = 3 independent experiments). *P-value <0.05. (B) Western blot analysis with the indicated antibodies of HeLa cells,
48 h after transfection with siHNRNPD or siCTR followed by 2-h treatment with 1 M CPT. GAPDH was assessed as a normalization control. The
values of band density corresponding to pCHK1 S345 and pRPA32 S4/8, normalized to the total protein levels, are reported. (C) Cell cycle profile of
HeLa cells, 48 h after transfection with siHNRNPD or siCTR, was analyzed through flow cytometry upon propidium iodide (PI) staining. (D) H2Ax
values were measured by FACS analysis in HeLa cells, transfected with the indicated siRNAs for 48 h, then treated with 1 M CPT for 2 h. The insets
report the percentage of H2Ax positive cells. (E) HeLa cells were transfected with the indicated siRNAs for 48 h, treated with 1M CPT for 2 h (T0)
followed by drug washout and incubation in CPT-free medium for additional 6 h (T6). H2AX foci were measured at T0 and T6 with the ImageJ software
analysis. Data represent the mean ± s.d. (n = 4 independent experiments). *P-value <0.05.
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Figure 3. HNRNPD regulates the DNA end-resection process. (A) FACS analysis of ssDNA formation in HeLa cells transfected with siCTR or siHN-
RNPD for 24 h, then pulse-labelled with 10MBrdU for additional 24 h and treated with 1MCPT for 2 h. HeLa cells were prepared for cytofluorimetric
analysis in non-denaturing conditions in order to quantify the percentage of positive ssDNA cells. The untreated condition (no DNA damage) reveals the
background level given in each cell type by the FITC-antibody detecting BrdU (in this case BrdU is entrapped within the double helix and cannot be
recognized by the antibody). Such background values, subtracted to the values obtained following CPT treatment, indicate a ∼3-fold decrease in single
strand DNA upon HNRNPD silencing. (B) To perform the SMART technique, HeLa cells (both siCTR and siHNRNPD) were pulse-labelled with 10 M
BrdU for 24 h then treated with 1 MCPT for 2 h before spreading onto Silane Prep Slides. Immunofluorescence was performed with the BrdU antibody.
Two representative images for each cell type (siCTR and siHNRNPD) are shown. (C) BrdU signal intensity of SMART technique analyzed by ImageJ
software. Data represent the mean ± standard deviation (s.d.). (n = 2 independent experiments). *P-value <0.05. (D) HeLa ER-AsiSI were transfected
with siCTR or siHNRNPD for 48 h followed by treatment with 300 nM of 4-OHT. The Real-time qPCR was performed on the genomic DNA with the
indicated primers amplifying regions including the positions at 364 and 1754 bp downstream from the DSB, as depicted. The values of %ssDNA are
reported as the mean ± s.d. (n = 4 independent experiments) and were calculated as follows: %ssDNA = 1/[(2Ct-1) + 0.5] × 100 (83). **P-value <0.01;
*P-value <0.05. (E) HeLa cell lines were transfected with the indicated siRNAs for 48 h treated or not with 1 M CPT for 2 h; before fixative, cells were
pre-extracted with the CSK + 0.1% Triton X100 + 0.3 g/ml RNase A followed by incubation with indicated antibody. RPA32 values were analyzed
through flow cytometry. (F) ChIP experiments of HeLa ER-AsiSI, treated or mock treated with 300 nM 4-OHT for 1 h, were performed by using either an
HNRNPD antibody or control IgGs (Ab-). The HNRNPD chromatin binding ability was measured, as a percentage of immunoprecipitated input, from
qPCR values of an 80 bp amplicon including the AsiSI site. Data represent the mean ± s.d. (n = 4 independent experiments). *P-value <0.05. (G) HeLa
DR-GFP cells were transfected with the plasmid encoding the SceI restriction enzyme in presence of siCTR, siHNRNPD or siMRE11 followed by FACS
analysis measurement of GFP levels used to calculate %HR frequency compared with siCTR which was set as 100%. Data represent the mean ± s.d. (n =
3 independent experiments), **P-value <0.01.
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HR efficiency of ∼50% compared with the control siRNAs
and similarly to the effect achieved with MRE11 downreg-
ulation (Figure 3G and Supplementary Figure 3a). Collec-
tively, these data suggest a possible role of HNRNPD in
the regulation of DNA end-resection, probably in the ini-
tial steps of the process.
HNRNPDknockout sensitize HeLa cells to PARP inhibition
To verify and confirm the above experiments, we generated,
through the CRISPR/Cas9 system, HNRNPD–/– HeLa
cell clones (Figure 4A). Western blot analysis showed the
knockout of all HNRNPD protein isoforms in two HeLa
HNRNPD–/– clones (Figure 4B). In order to confirm the
alteration of DNA end-resection markers, as observed in
HeLa siHNRNPDcells (Figure 2b), we treatedHNRNPD–
/– cells with CPT followed by western blot analysis showing
a marked reduction of both RPA32 S4/S8 and CHK1 S345
phosphorylation (Figure 4C and Supplementary Figure 3b,
respectively). To assess whether HNRNPD re-expression in
HeLa HNRNPD–/– cell clones recovers the DDR func-
tion, we generated pFLAG-HNRNPD expression vectors
with the four isoforms mutated in the PAM sequence (to
avoid Cas9 cut). The expression of different HNRNPD iso-
forms (p45, p42, p40) proved able to increase pRPA32 S4/8
phosphorylation, uponCPT treatment and each functioned
in combination with p45 (Figure 4D and Supplementary
Figure 3c), whereas p37 (Supplementary Figure 3d) did not.
To demonstrate the direct involvement of HNRNPD in the
DNAresection process, we performed an in vitro assay using
digested plasmids with either 3′ protruding, 5′ protruding
or blunt ends and incubated them with the nuclear extract
derived from wt HeLa or HNRNPD–/– cells. Remarkably,
HNRNPD loss abolished the DNA degradation ability ob-
served with the wt extracts (Figure 4E, Supplementary Fig-
ure 3e–g).
Finally, to assess the potential clinical relevance of HN-
RNPD, we assessed whether its knockout could sensitize
HeLa cells to treatment with CPT, the precursor of a broad
class of antineoplastic drugs widely used for the treatment
of several tumours (55). So, we performed a clonogenic
assay and found that both the HNRNPD–/– clones cl4
and cl10 showed a slightly increased sensitivity to the cy-
totoxic effects of CPT resulting in a 6 nM IC50 for wt
HeLa compared with 4.5 nM IC50 for both cl4 and cl10
HNRNPD–/– clones (Figure 4F). As HR proteins, such
as BRCA1/2, have been described to be synthetic lethal
with the inhibition of other repair factors, such as the
poly (ADP-Ribose) polymerase inhibitor 1, PARP1 (56), we
then treated both wt HeLa cells and the two HNRNPD–
/– clones, with the PARP1 inhibitor olaparib. Indeed, we
found that the absence of HNRNPD sensitized HeLa cells
to olaparib-induced growth inhibition. Interestingly, ola-
parib, at the highest concentration tested, remarkably re-
duced clonogenic ability in HeLa cells null for HNRNPD
whereas it did not reach 50% inhibition of colony formation
inwtHeLa cells (Figure 4F). Taken together, these data sug-
gest that HNRNPD modulation could be used to sensitize
cancer cells to various antitumoral agents. It will have to be
further established whether re-expression of HNRNPD (or
specific isoform combinations) in knockout cells is able to
recover the DNA repair ability (in DNA end resection as-
says) and reverse CPT and olaparib sensitivity.
HNRNPD interacts with SAF-A and its silencing induces R-
loop accumulation nearby the DNA lesions
The heterogeneous nuclear ribonucleoproteins regulate var-
ious aspects of cell biology such as mRNA export, localiza-
tion, DNA repair and resolution of R-loop structures (57–
59). One of these, previously involved in the DNA damage
response, is HNRNPU (also known as SAF-A) (59). So, we
investigated whether SAF-A and HNRNPD could possibly
interact. We transfected HeLa cells with vectors expressing
SAF-A-FLAG and HNRNPD-HA and found through re-
ciprocal co-immunoprecipitation experiments that the two
proteins are indeed able to interact (Figure 5A and Sup-
plementary Figure 4a). The protein lysates, before the im-
munoprecipitation, were treated with RNase A and EtBr
to remove mRNA and DNA, respectively. Through ChIP
assay, near the AsiSI cut sites, we found reduced SAF-A lo-
calization upon DSB induction in HNRNPD silenced cells
compared with control cells (Figure 5B). Consistently, by
means of chromatin enriched purification, in the presence
of RNase A, we confirmed a reduced chromatin loading of
SAF-A upon DNA damage in HNRNPD knockout cells
(Supplementary Figure 4b), suggesting that HNRNPD si-
lencing affects SAF-A localization on the damaged DNA.
As SAF-A dynamics (presence/exclusion) on the dam-
aged sites was associated with R-loop modulation (59), we
performed a DRIP assay to analyze R-loops near the DSB
induced by AsiSI in HNRNPD silenced cells (Figure 5C).
Quantitative RT-PCR analysis (with a primer pair ampli-
fying a DNA region distant ∼600 bp from the enzyme
cut site) showed an increased number of R-loops in siHN-
RNPD cells compared with the control cells.
Recently, R-loops were described to be essential regula-
tor of DNA end-resection favouring the DDR, although
with a seemingly contrasting function (60,61). Indeed, while
DNA:RNA hybrid presence on damaged DNA seems to
promote repair (likely in an earlier phase), their proper re-
moval is also required to this aim. In fact, overexpression of
RNase H1, which digests the RNA within DNA:RNA hy-
brids thereby reducing R-loop occurrence, reduced DNA
resection and repair (60). So, we analyzed the effect of
RNase H1 ectopic overexpression in HNRNPD KO cells
upon CPT treatment (Figure 5D). RNase H1 expression
was able to recover RPA32 S4/8 phosphorylation defects,
further supporting the idea that HNRNPD acts favouring
R-loop removal for a proper DNA-end resection. More-
over, as the RNA pol II generates the mRNA that can in-
vade the duplex of resected DNA favoring R-loop forma-
tion (61), we assessed whether the selective inhibition of
RNA pol II through -amanitin could also rescue the de-
fective RPA32 S4/8 phosphorylation upon DNA damage
observed in HNRNPD KO cells. Indeed, -amanitin pre-
treatment (62) functioned similarly toRNaseH1 in rescuing
RPA32 S4/8 phosphorylation upon damage in cells lacking
HNRNPD function (Figure 5E). Overall, these data argue
for a crucial role of HNRNPD in the R-loop resolution,
possibly contributing at least to some extent with SAF-A
recruitment, for a proper DDR.
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Figure 4. HNRNPD knockout affects the DNA damage response and sensitizes cells to CPT and olaparib treatment. (A) Schematic representation of the
CRISPR/Cas9 strategy used to develop the HNRNPD ko cells. The sgRNA guide is indicated in red. (B) Western Blot analysis of HeLa HNRNPD ko
clones with either theMillipore (07-260, left panel), or the Cell signalling (D6O4F, right panel), antibody. The asterisk indicates a non-specific band, which
was detected by the Millipore antibody. GAPDH was used as a loading control. (C) Western blot analysis of DNA damage response markers following
treatment with 1 M CPT for 2 h in HeLa wt cells and HNRNPD knockout cell clones. Lamin A/C was used as a loading control. The values of band
density corresponding to pRPA32 S4/8, normalized to the total protein levels, are reported. (D) HeLa HNRNPD–/– cl10 cells were transfected with the
pCEFL-HA HNRNPD isoforms with the PAM mutated sequence for 48 h followed by 1M CPT for additional 2 h followed by western blot analysis
with the indicated antibodies. Different expression levels are likely dependent on either a different transfection efficiency or by plasmids co-transfection.
Lamin A/C was used as a loading control. The values of band density corresponding to pRPA32 S4/8, normalized to the total protein levels, are reported.
(E) DNA end-resection assay in vitro with the nuclear protein extracts from HeLa wt and HNRNPD cl10 cell lines. Linearized plasmid with either 3′,
blunt or 5′ overhangs were incubated with protein extracts for the indicated time points and run on a 0.8% agarose gel + EtBr. (F) HeLa and HNRNPD
cell clones were treated with the indicated drugs at crescent concentrations for ten days followed by staining with crystal violet. Asterisks indicate: ***P-
value <0.001; **P-value <0.01; *P-value <0.05, respectively.
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Figure 5. HNRNPD regulates R-loops through the localization of SAF-A protein. (A) HeLa cells were transfected with either SAF-A FLAG or
HNRNPD-HA, incubated for 48 h and treated or not for 2 h with 1M CPT. Protein lysates were incubated 30 min on ice with 0,3 g/ml of RNase
A and 50 g/ml of EtBr followed by centrifugation to remove the debris. Immunoprecipitation was conducted with anti-HA antibody over night at +4◦C.
An antibody against total RPA32 was used as a DNA damage control. (B) HeLa ER-AsiSI were transfected with the indicated siRNAs in combination
with the plasmid coding for SAF-A-FLAG for 48 h and treated or mock treated with 300 nM 4-OHT for 1 h. ChIP analysis was performed by using either
an anti FLAG antibody or control IgGs (Ab–). SAF-A chromatin binding ability was measured as a percentage of immunoprecipitated input, from qPCR
values of a 200 bp amplicon upstream to AsiSI cut site. Data represent the mean ± s.d. (n = 3 independent experiments). *P-value <0.05. (C) HeLa cells
were transfected with the indicated siRNAs for 48 h followed by induction of DSBs through the AsiSI enzyme. The immunoprecipitation was carried out
with the anti-DNA:RNA hybrid S9.6 antibody over night at +4◦C. Data represent the mean ± s.d. (n = 3 independent experiments). *P-value <0.05. (D)
HeLa HNRNPD ko cell line cl10 was transfected with RNaseH GFP coding plasmid and incubated 48 h followed by 1 M CPT treatment and western
blot analysis. Lamin A/C was used as a normalization control. Densitometric analysis of pRPA32 S4/8 activation was carried out through the ImageJ
software. (E) HeLa HNRNPD ko cl10 was treated with 10 M of -amanitin for 6 h followed by co-treatment with 1 M CPT (where indicated) for
additional 2 h followed by western blot analysis. Lamin A/C was used as a normalization control. Densitometric analysis of pRPA32 S4/8 activation was
carried out through the ImageJ software.
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DISCUSSION
DNA damage repair defects are a leading cause of genomic
instability, which is one of the main features enabling can-
cer development (63). Many sources of DNA damage, en-
dogenous or environmental, can harm the genome acti-
vating the cellular response. DNA repair defects predis-
pose to various diseases such as cancer and accelerate ag-
ing (64). Recently, RBPs were described to regulate the
DDR both through their functions within RNA biology
(such as splicing regulation) (65) and in the processing of
DNA lesions (66). Among these, the RBP HNRNPD was
shown to regulate the mRNA fate of many DDR proteins
in response to DNA damage (40). The alteration of HN-
RNPD expression was found to affect many genes underly-
ing tumorigenic phenotypes owing to deregulation of their
post-transcriptional control (67); interestingly, HNRNPD
knockout mice showed accelerated aging associated with
telomere erosion, increased inflammatory cytokines and
cellular senescence (52).
Here, we performed a proteomic screening, using a syn-
thetic DNA end-resection intermediate, and identified HN-
RNPD as a new player, directly involved, in the DDR.
HNRNPD has four different splicing isoforms (p45, p42,
p40, p37) and we identified, through LC-MS analysis, pep-
tides corresponding specifically to the p45 and p40 pro-
teins. However we found that all HNRNPD isoforms are
able to bind the HeLa chromatin and the synthetic biotiny-
lated DNA. Consistently with our data HNRNPD was re-
cently identified, along with the MRN complex, as bound
to damaged DNA in Xenopus l. egg extracts (68). Indeed,
HNRNPD proved able to bind the synthetic structure in
vitro and the binding was independent of the RPA com-
plex; the HNRNPD binding was not sequence specific but
dependent on free ends, consistent with a possible recogni-
tion of randomly inducedDNADSBs. The reduced binding
of HNRNPD to the biotin-tagged ends demonstrated the
reliability of the screening methods and the specific bind-
ing of the protein to the DNA. We also found that HN-
RNPD was able to bind chromatin DNA, which is a pre-
rogative of DNA repair factors (69). By generation of HN-
RNPD deletion mutants we demonstrated that its DNA
binding activity, both in vivo and in vitro, was not dependent
on RRMs, which are responsible of the HNRNPD bind-
ing to the human single strand telomeric repeats (45). Here,
we found that the DNA binding ability of HNRNPD re-
quired the C-terminal protein domain. We have not been
able to achieve expression of a mutant containing the C-
terminal only, devoid of RRM motifs, to demonstrate for-
mally the DNA binding ability of the sole C terminal do-
main. However, the use of RNase A in all the DNA binding
experiments suggests that HNRNPD binds DNA indepen-
dently of its (RRM-mediated) RNA regulatory function.
Indeed, HNRNPD was previously classified as a DNA-
and RNA-binding protein (DRBP) (70). Interestingly, the
C-terminal domain contains a glycine–arginine rich do-
main (GAR) (46); this domain is common to many pro-
teins with different functions including MRE11, in which
the methylation of the arginine within the GARmotif is es-
sential for its localization to the DSBs in vivo (71). Intrigu-
ingly, the regulation of GAR methylation depends on the
family of protein arginine methyltransferases (PRMTs) of
which PRMT6 is responsible for HNRNPD protein methy-
lation (72). However, DNA damage did not increase HN-
RNPD chromatin fraction suggesting that, upon damage,
HNRNPD re-localizes from unperturbed DNA to dam-
age sites. Consistently, HNRNPD was able to re-localize
on the DNA damaged induced foci suggesting a possible
role in the recognition of the lesion favouring its repair.
This would be in accordance with the correct H2Ax ac-
tivation and the impaired foci resolution observed in siH-
NRNPD HeLa cells, in a manner similar to what occurs in
siMRE11 HeLa cells. In this scenario, it seems possible that
post-translational modifications of HNRNPD, within or
not the C-terminal domain, might direct its re-localization
onto DNA damage sites and affect the DNA binding activ-
ity.
The DNA end-resection process is characterized by pro-
tein localization, on the sites of damage, which are essential
for the generation of the ssDNA tail rapidly coated by RPA
complex in order to promote the RAD51 loading and the
strand exchange (73). Although we did not investigate the
temporal loading of HNRNPD with regard to the DNA
end-resection cascade, we demonstrated its direct involve-
ment in the process showing impairment of ssDNA for-
mation upon CPT treatment, assessed through BrdU anal-
ysis, but not upon the replication stress induced by the
HU treatment. Indeed, FACS analysis showed that HN-
RNPD silencing in HeLa reduced, upon DNA damage, the
chromatin localization of RPA32, readout of ssDNA for-
mation. In particular, HNRNPD silencing affected DNA-
end resection at both 364 and 1754 nucleotides from the
AsiSI-induced DSBs, without altering the mRNA levels
of the principal players underlying this process. The ChIP
analysis of HNRNPD onto the DSBs sites induced by the
AsiSI enzyme, confirmed the physical presence of the pro-
tein near the DNA lesions. Consistently, HNRNPD silenc-
ing reduced the cell ability to repair the DSBs through the
HR, measured by a GFP reporter assay (20), mirroring the
effect of MRE11 silencing (74). The reduced phosphoryla-
tion of CHK1 and RPA32, in HNRNPD silenced cells sug-
gest its involvement in the processing of the lesions rather
than in its signalling as confirmed by the normal activation
of the DNA damage signalling marker H2Ax (51). More-
over, the unaffected cell cycle distribution of HeLa siHN-
RNPDwith respect to siCTR cells confirms that the check-
point impairment was not due to an indirect effect.
Consistently with HNRNPD silencing, the CRISPR-
Cas9mediatedHNRNPDknockout also affected theDDR
by reducing CHK1 S345 phosphorylation and, in particu-
lar, the end-resection process as shown by reduced RPA32
S4/8 phosphorylation and impairedDNA resection in vitro.
HNRNPD silencing affected ssDNA formation uponDNA
damage induced by CPT but not upon DNA replica-
tion block through HU, suggesting a specific role of HN-
RNPD in DNA repair. Interestingly, HNRNPD knockout
increased cell sensitivity to both CPT and the PARP1 in-
hibitor olaparib, as occurs with loss of other proteins in-
volved in HR such as BRCA1/2–/– cells (75), providing the
framework for a possible use of HNRNPD modulation to
sensitize cancer cells towidely used antitumoral agents. Var-
ious mechanisms have been proposed to explain why HR
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Figure 6. Schematic representation of the hypothesized HNRNPD mech-
anism of action during homologous recombination. (A) In HeLa wild type
cells, upon DNA damage, HNRNPD is relocated to DNA damage sites.
Upon damage also SAF-A is located near the DNA lesion and both pro-
teins are associated with a proper removal of the R-loop structures dur-
ing the DNA end-resection process. (B) In HNRNPD silenced cells, SAF-
A does not localize onto damaged sites and R-loops accumulate impair-
ing the DNA end-resection and ultimately the homologous recombination
process.
defective cells (such as BRCA1/2–/–) develop sensitivity to
inhibitors of PARP1 activity beyond the originalmodel sug-
gesting that PARP1 inhibition increases the rate of single
strand breaks, which, during replication, are converted to
DSBs thus implying repair through HR (76). Despite the
underlying mechanism involved, the fact that HNRNPD
knockout sensitized cells to PARP1 inhibition through ola-
parib strongly supports its role in HR herein uncovered
(76).
The HNRNPs family represents a large protein fam-
ily involved in many cellular processes and diseases, such
as neurodegenerative diseases and cancer (77,78). These
proteins act within mega- or mini-complexes comprising
two or more HNRNPs, providing them a functional ver-
satility. The best characterized role of HNRNPs family is
the regulation of mRNA processing (57); recently, addi-
tional functions were described including a role in the DNA
damage response (58,59). In particular, HNRNPUL1 was
described to be involved in the regulation of DNA end-
resection downstream of MRE11 and CTIP favouring the
loading of BLM protein. More recently, BLM-DNA2 me-
diated long-range resection was found to be regulated by
CTIP (79). Here, we found that the localization of HN-
RNPD to the damaged sites was independent of MRE11,
CTIP or EXOI because it was not affected by their silenc-
ing (data not shown). So, our findings seem to suggest a
role of HNRNPD upstream the DNA-end resection pro-
cess, independently of MRE11, CTIP and EXOI. However
it will have to be determined whether HNRNPD impacts
on MRN complex recruitment onto damaged sites.
Emerging evidences have implicated R-loop structures in
the DNA damage response (15,80) and RNA binding pro-
teins in the regulation of these structures (59). SAF-A, an-
other HNRNP, was previously involved in the regulation of
DNA repair and associated with the regulation of R-loop
structures (59). Here we found that HNRNPD and SAF-A
are able to physically interact in a way that seems indepen-
dent of DNA and/or mRNA presence. The RBD domain
of SAF-Awas previously found important for the exclusion
of the HNRNP from damaged sites and the authors per-
formed LC-MS analysis of SAF-A-RBD to identify puta-
tive protein partners (59). HNRNPD was not found in this
screening probably because the small SAF-A-RBD used as
bait is not necessary for the interaction. Indeed, our data
indicate that SAF-A/HNRNPD interaction requires the
SPRY domain of SAF-A (data not shown), although in-
teraction between HNRNPD and SAF-A endogenous pro-
teins still needs to be assessed. Interestingly, SAF-A local-
izes onto DNA breaks with a peculiar dynamics and cor-
relates with DNA:RNA hybrid resolution (59). We herein
demonstrated an increased amount of DNA:RNA hybrids
in siHNRNPD HeLa cells with respect to the controls at
the AsiSI induced DSBs sites, measured through the DRIP
analysis. We also observed a reduced chromatin DNA load-
ing of SAF-A protein in response to CPT treatment in the
absence of HNRNPD. Consistently, SAF-A ability to lo-
calize near the AsiSI-induced DSBs was reduced in HeLa
siHNRNPD cells, measured through ChIP assay. Overall
these data further support a role of heterogeneous nuclear
ribonucleoproteins in the regulation of R loops at damaged
sites, which deserves further investigation.
The relevance of DNA:RNA hybrid resolution for a
proper DNA repair has been recently described. It has been
shown that the formation of R-loop at the DSBs is facili-
tated by the initial 5′-end resection, operated by the MRN
complex, and, consistently, the inhibition of RNase H ac-
tivity in S. Pombe decreased RPA loading, near the DSBs
(81). The crosstalk between RNase H and RPA is thought
to be evolutionary conserved (33). In light of these findings
the reduced RPA32 loading, measured by FACS and ChIP
analysis upon DNA damage, which we observed in siHN-
RNPD cells, is likely indicative of a defective R-loop resolu-
tion. Indeed, ectopic expression ofRNaseH1 or-amanitin
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treatment restored RPA32 S4/8 phosphorylation in HN-
RNPD KO cells suggesting that R-loop accumulation im-
pairs HNRNPD-mediated DNA end resection. The un-
derlying mechanism whereby HNRNPD regulates R loop
structures, upon DNA damage but possibly also in the ba-
sic transcriptional setting, however, still needs to be char-
acterized. Interestingly a recent study found HNRNPD (as
well SAF-A) as part of the DNA:RNA hybrid-interactome
identified through mass spectrometry analysis (82) further
supporting their possible role in R loop regulation. In sum-
mary, we identified HNRNPD as a novel factor involved in
the DNA end-resection process, a key step essential for the
HR-mediated repair, associated with proper R-loop resolu-
tion (Figure 6).
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